Immatics IMTX
NASDAQ IMTX
$9.56 +0.10 (+1.06%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2026)

Immatics (IMTX) posted Non-Current Deffered Revenue of $21.6 million for Q4 2025, down 30.82% sequentially from $31.2 million in Q2 2025, and down 40.88% YoY from $36.5 million in Q4 2024.

Analysis

Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends

Immatics has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $21.6 million in Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 40.88% year-over-year to $21.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.6 million (down 40.88% YoY) and the FY2025 annual result came in at $20.9 million, down 43.34% from the prior year.
  • Non-Current Deffered Revenue declined to $21.6 million in Q4 2025 per IMTX's latest filing, from $31.2 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $124.3 million in Q4 2023 and troughed at $21.6 million in Q4 2025.
  • A 5-year average of $68.3 million and a median of $66.6 million in 2021 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue surged 64.28% in 2022, then plunged 70.63% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $55.2 million in 2021, then soared by 40.1% to $77.3 million in 2022, then surged by 60.82% to $124.3 million in 2023, then sank by 70.63% to $36.5 million in 2024, then plunged by 40.88% to $21.6 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $21.6 million, $31.2 million, and $36.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Immatics 1.17 Bn 711.21 Mn - 15.85 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.85 Mn
Mar 31, 2026 18.59 Mn
Dec 31, 2025 21.58 Mn
Sep 30, 2025 26.24 Mn
Jun 30, 2025 31.20 Mn
Mar 31, 2025 30.68 Mn
Dec 31, 2024 36.50 Mn
Sep 30, 2024 57.76 Mn
Jun 30, 2024 81.09 Mn
Mar 31, 2024 99.25 Mn
Dec 31, 2023 124.30 Mn
Sep 30, 2023 59.72 Mn
Jun 30, 2023 58.32 Mn
Mar 31, 2023 70.07 Mn
Dec 31, 2022 77.29 Mn
Sep 30, 2022 104.07 Mn
Jun 30, 2022 123.05 Mn
Mar 31, 2022 76.08 Mn
Dec 31, 2021 55.17 Mn
Sep 30, 2021 61.60 Mn